期刊
CLINICAL ONCOLOGY
卷 25, 期 6, 页码 378-387出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2013.01.003
关键词
Risk; serious complications; stereotactic ablative radiotherapy
类别
资金
- Varian Medical Systems
- Department of Defense (USA)
- Accuray Incorporated
The clinical applications of stereotactic body radiotherapy or stereotactic ablative radiotherapy (SABR) for the treatment of primary and metastatic tumours of different organ sites have been expanding rapidly in the recent decade. SABR requires advanced technology in radiotherapy planning and image guidance to deliver a highly conformal ablative dose precisely to targets (or tumours) in the body. Although this treatment modality has shown promising results with regard to tumour control, some serious complications have been observed and reported. In order to achieve a favourable therapeutic ratio, strategies to mitigate the risk of complications must be in place. This overview will summarise the reported serious complications caused by SABR and strategies to mitigate the risk will be discussed. (C) 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据